Headache in patients with systemic lupus erythematosus: a pilot study

Introduction Headache is a symptom frequently reported by patients with Systemic Lupus Erythematosus (SLE), but it remains controversial as to whether the prevalence is higher than in the those without the disease and if there is an association with disease activity. Objectives 1) to compare the pre...

Full description

Saved in:
Bibliographic Details
Published inRevista Headache Medicine (Online) p. 28
Main Authors Oliveira, Igor de, Fontes, Bruno Rodrigo de, Mariz, Henrique de Ataíde, Duarte, Angela Luzia Branco Pinto, Rocha-Filho, Pedro Augusto Sampaio
Format Journal Article
LanguageEnglish
Published 27.10.2022
Online AccessGet full text

Cover

Loading…
More Information
Summary:Introduction Headache is a symptom frequently reported by patients with Systemic Lupus Erythematosus (SLE), but it remains controversial as to whether the prevalence is higher than in the those without the disease and if there is an association with disease activity. Objectives 1) to compare the prevalence, monthly frequency and impact of headaches between patients with SLE and a control group without the disease and 2) to compare the prevalence, monthly frequency and impact of headaches between patients with active SLE and those without disease activity Methods This is a case-control study. The case group consisted of patients diagnosed with SLE in regular follow-up at the Rheumatology outpatient clinic of the Hospital das Clínicas, UFPE, excluding those with a previous diagnosis of secondary headache or overlapping autoimmune diseases. A control group, matched for sex and age, consisted of hospital staff and friends and relatives of patients who had no previous diagnosis of secondary headache or autoimmune disease. Data on SLE and headache were collected through interviews and questionnaires administered by a neurologist. Headache impact was assessed using the Headache Impact Test (HIT-6) scale, anxiety and depression symptoms were assessed using the Hospital Anxiety and Depression Scale (HADS) and disease activity was evaluated using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2K modified scale, considering clinical and laboratory data from the last 30 days. All participants who reported at least one headache attack in the last year were considered as having headache and specific diagnoses were made based on the 3rd edition of the International Classification of Headache Disorders. SLE patients with SLEDAI-2K ≥ 6 were considered as having disease activity. Statistical analyzes were performed in SPSS 28.0 with significance defined as p < 0.05... (To see the complet abstract, please, check out the PDF.)
ISSN:2763-6178
2763-6178
DOI:10.48208/HeadacheMed.2022.Supplement.28